Cargando…

Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2022;46:630-9)

Detalles Bibliográficos
Autor principal:	Huh, Ji Hye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Diabetes Association 2022
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723197/ https://www.ncbi.nlm.nih.gov/pubmed/36455532 http://dx.doi.org/10.4093/dmj.2022.0374

Ejemplares similares

Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2022;46:630-9)
por: Seo, Da Hea, et al.
Publicado: (2022)

Association between Type 2 Diabetes Mellitus and Brain Atrophy: A Meta-Analysis (Diabetes Metab J 2022;46:781-802)
por: Min, Se Hee
Publicado: (2022)

Association between Type 2 Diabetes Mellitus and Brain Atrophy: A Meta-Analysis (Diabetes Metab J 2022;46:781-802)
por: Zhang, Tianqi, et al.
Publicado: (2022)

Association between Metabolic Syndrome and Microvascular Complications in Chinese Adults with Type 1 Diabetes Mellitus (Diabetes Metab J 2022;46:93-103)
por: Huang, Qianwen, et al.
Publicado: (2022)

Association between Metabolic Syndrome and Microvascular Complications in Chinese Adults with Type 1 Diabetes Mellitus (Diabetes Metab J 2022;46:93-103)
por: Kim, Gyuri
Publicado: (2022)

Waist Circumference and Body Mass Index Variability and Incident Diabetic Microvascular Complications: A Post Hoc Analysis of ACCORD Trial (Diabetes Metab J 2022;46:767-80)
por: Hukportie, Daniel Nyarko, et al.
Publicado: (2023)

Waist Circumference and Body Mass Index Variability and Incident Diabetic Microvascular Complications: A Post Hoc Analysis of ACCORD Trial (Diabetes Metab J 2022;46:767-80)
por: Cho, Yun Kyung
Publicado: (2023)

Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658–62)
por: Kim, Hwi Seung, et al.
Publicado: (2022)

Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658–62)
por: Kawada, Tomoyuki
Publicado: (2022)

Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2021;45:698-707)
por: Han, Eugene, et al.
Publicado: (2021)

Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2021;45:698-707)
por: Kim, Mi-kyung
Publicado: (2021)

Association of Myosteatosis with Nonalcoholic Fatty Liver Disease, Severity, and Liver Fibrosis Using Visual Muscular Quality Map in Computed Tomography (Diabetes Metab J 2023;47:104-17)
por: Roh, Eun
Publicado: (2023)

Association of Myosteatosis with Nonalcoholic Fatty Liver Disease, Severity, and Liver Fibrosis Using Visual Muscular Quality Map in Computed Tomography (Diabetes Metab J 2023;47:104-17)
por: Kim, Hwi Seung, et al.
Publicado: (2023)

The Determinants of Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
por: Dai, Chia-Yen, et al.
Publicado: (2022)

Age at Diagnosis and the Risk of Diabetic Nephropathy in Young Patients with Type 1 Diabetes Mellitus (Diabetes Metab J 2021;45:46-54)
por: Yang, Ye Seul, et al.
Publicado: (2021)

Age at Diagnosis and the Risk of Diabetic Nephropathy in Young Patients with Type 1 Diabetes Mellitus (Diabetes Metab J 2021;45:46-54)
por: Baek, Jong Ha, et al.
Publicado: (2021)

Diabetes and Nonalcoholic Fatty Liver Disease
por: Kantartzis, Konstantinos, et al.
Publicado: (2012)

Nonalcoholic fatty liver disease and diabetes
por: Bellini, Maria Irene, et al.
Publicado: (2022)

Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
por: Seo, Da Hea, et al.
Publicado: (2022)

Change in Liver Fibrosis Associates with Progress of Diabetic Nephropathy in Patients with Nonalcoholic Fatty Liver Disease
por: Terasaka, Yoshiko, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease and Abdominal Fat Accumulation According to Vitamin D Status in Patients with Type 2 Diabetes (J Obes Metab Syndr 2018;27:53–60)
por: Hwang, Juchul, et al.
Publicado: (2018)

Nonalcoholic Fatty Liver Disease and Abdominal Fat Accumulation According to Vitamin D Status in Patients with Type 2 Diabetes (J Obes Metab Syndr 2018;27:53–60)
por: Kim, Bo-Yeon, et al.
Publicado: (2018)

Response: Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease (J Obes Metab Syndr 2019;28:129-38)
por: Chung, Goh Eun, et al.
Publicado: (2020)

Letter: Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease (J Obes Metab Syndr 2019;28:129-38)
por: Jung, Chan-Hee
Publicado: (2020)

Letter: Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease (J Obes Metab Syndr 2019;28:129-38)
por: Kwon, Hyuktae
Publicado: (2020)

Response: Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease (J Obes Metab Syndr 2019;28:129-38)
por: Chung, Goh Eun, et al.
Publicado: (2020)

Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
por: Dharmalingam, Mala, et al.
Publicado: (2018)

Diagnostic Performance of the Fibrosis-4 Index and Nonalcoholic Fatty Liver Disease Fibrosis Score in Lean Adults With Nonalcoholic Fatty Liver Disease
por: Park, Huiyul, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease, Diabetes Mellitus and Cardiovascular Disease: Newer Data
por: Mavrogiannaki, A. N., et al.
Publicado: (2013)

Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Amjad, Waseem, et al.
Publicado: (2023)

The Coexistence of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
por: Kosmalski, Marcin, et al.
Publicado: (2022)

Risk factors associated with nonalcohol fatty liver disease and fibrosis among patients with type 2 diabetes mellitus
por: Zhao, Hongli, et al.
Publicado: (2018)

Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease
por: Barb, Diana, et al.
Publicado: (2021)

Banting memorial lecture 2022: ‘Type 2 diabetes and nonalcoholic fatty liver disease: Partners in crime’
por: Byrne, Christopher D.
Publicado: (2022)

Letter: Hepatic Fibrosis and Steatosis in Metabolic Syndrome (J Obes Metab Syndr 2022;31:61-9)
por: Seo, Young-Gyun
Publicado: (2022)

Independent Impact of Diabetes on the Severity of Coronavirus Disease 2019 in 5,307 Patients in South Korea: A Nationwide-Cohort Study (Diabetes Metab J 2020;44:737–46)
por: Kim, Kyuho, et al.
Publicado: (2020)

Independent Impact of Diabetes on the Severity of Coronavirus Disease 2019 in 5,307 Patients in South Korea: A Nationwide Cohort Study (Diabetes Metab J 2020;44:737–46)
por: Moon, Sun Joon, et al.
Publicado: (2020)

Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective
por: Rhee, Eun-Jung
Publicado: (2019)

Nonalcoholic Fatty Liver Disease in Diabetics: The Role of Hepatologist
por: Khandelwal, Reshu, et al.
Publicado: (2022)

Response: The Differential Association between Muscle Strength and Diabetes Mellitus According to the Presence or Absence of Obesity (J Obes Metab Syndr 2019;28:46–52)
por: Koo, Bo Kyung
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dsvl2t8qncge2f3sbj7pgouled